6 terminated. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 6 |
| Phase 1 | 2 | Terminated 2 |
Follow Paraganglioma: new trials by email Literature Review of Paraganglioma trials Research Report on Paraganglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma EO2401, Nivolumab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 1 / Phase 2 | Terminated | Enterome | 70 | 2020-07-23 | 2026-01-30 |
| A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer SGI-110 (guadecitabine) - Paraganglioma, Gastrointestinal Stromal Tumors | Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2017-08-16 | 2026-02-18 |
| GA-68 DOTA-TOC of Somatostatin Positive Malignancies Computed Tomography (CT), Gallium Ga 68-Edotreotide, Magnetic Resonance Imaging (MRI) - Neuroendocrine Tumor, Paraganglioma | Phase 1 / Phase 2 | Terminated | University of California, San Francisco | 300 | 2014-06-23 | 2019-11-12 |
| Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma Laboratory Biomarker Analysis, Pazopanib Hydrochloride - Extra-Adrenal Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 7 | 2011-05-01 | 2017-09-21 |
| RAD001 and Erlotinib in Patients With Neuroendocrine Tumors RAD001, erlotinib - Neuroendocrine Tumors | Phase 2 | Terminated | University of California, San Francisco | 17 | 2009-06-25 | 2020-09-29 |
| Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors octreotide acetate, yttrium Y 90 resin microspheres - Head and Neck Cancer, Islet Cell Tumor | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 10 | 2003-12-01 | 2012-05-18 |
Pheochromocytoma (5) · Carcinoid Tumor (2) · Neuroendocrine Tumors (2) · Adenoma, Islet Cell (1) · Adrenocortical Carcinoma (1) · Carcinoma, Islet Cell (1) · Carcinoma, Medullary (1) · Carcinoma, Renal Cell (1) · Gastrinoma (1) · Gastrointestinal Stromal Tumors (1) · Glucagonoma (1) · Head and Neck Neoplasms (1) · Insulinoma (1) · Kidney Neoplasms (1)
Neoplasms by Histologic Type (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Adenocarcinoma (5) · Carcinoma (5) · Neoplasms (5) · Neoplasms, Glandular and Epithelial (5) · Neuroendocrine Tumors (4) · Neoplasms by Site (3) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Adenoma (1)
Erlotinib Hydrochloride (1) · Everolimus (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Octreotide (1) · gallium Ga 68 dotatate (1) · guadecitabine (1) · pazopanib (1)
National Cancer Institute (NCI) (2) · University of California, San Francisco (2) · Enterome (1) · Vanderbilt-Ingram Cancer Center (1)
United States (6) · Denmark (1) · France (1) · Germany (1) · Hong Kong (1) · Italy (1) · Netherlands (1) · Singapore (1) · Spain (1) · Sweden (1)
Emily K. Bergsland, MD (1) · Jean-Michel Paillarse (1) · John W Glod, M.D. (1) · Keith Bible (1) · Steven G. Meranze, MD (1) · Thomas A Hope, MD (1)
N01CM00039 (1), N01CM00099 (1), N01CM62205 (1), P30CA015083 (1)